Condition

Myelofibrosis clinical trials and research

• 51Clinical trials
• 17NIH research projects
• 42Countries

Newest Myelofibrosis clinical trials

All recruiting trials (51)

• Elritercept vs. placebo for adults with myelofibrosis and anemia on ruxolitinib

  This study tests whether elritercept can improve anemia in adults with myelofibrosis who are taking ruxolitinib, compared with placebo.

  Recruiting at 11 sites Phase 3 Takeda · Gilbert, Arizona and 213 other locations · NCT07623161

• TQ05105 tablets for intermediate/high-risk myelofibrosis

  This phase 2 study tests TQ05105 tablets to see if they help people with intermediate or high-risk myelofibrosis who have not benefited from prior JAK inhibitors.

  Recruiting at 24 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 23 other locations · NCT07551427

• Ropeginterferon add-on to ruxolitinib in myelofibrosis

  This trial tests whether adding ropeginterferon alfa-2b to ongoing ruxolitinib treatment is safe and helpful for adults with myelofibrosis.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT07521046

• How a single dose of TQ05105 is processed and tolerated in people with liver impairment

  This study will give one dose of the medicine TQ05105 to adults with myelofibrosis who have different levels of liver impairment to see how the drug is handled by the body and whether it is safe.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Luoyang, Henan and 1 other locations · NCT07480824

• Pacritinib and Selinexor in JAK-inhibitor naive myelofibrosis with anemia and low platelets

  This trial tests whether combining pacritinib and selinexor helps patients with myelofibrosis who have anemia and low platelets and have not yet tried a JAK inhibitor.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · Westwood, Kansas and 2 other locations · NCT07447817

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• Nelfinavir to improve anemia in people with myelofibrosis by restoring iron delivery to the bone marrow

  This trial tests whether the antiviral drug nelfinavir can help people with myelofibrosis and anemia by raising hemoglobin and lowering blood markers of fibrosis.

  Recruiting Phase 1/2 University of California, Irvine · Orange, California · NCT07281781

• Nelfinavir to improve anemia in people with myelofibrosis by restoring iron delivery to the bone marrow

  This trial tests whether the antiviral drug nelfinavir can help people with myelofibrosis and anemia by raising hemoglobin and lowering blood markers of fibrosis.

  Recruiting Phase 1/2 University of California, Irvine · Orange, California · NCT07281781

• Rebecsinib dose test in relapsed/refractory sAML or high-risk myelofibrosis

  A new drug called rebecsinib is being tested to see if a certain dose is safe and helps people whose relapsed or hard-to-treat secondary AML or high-risk myelofibrosis respond.

  Recruiting at 3 sites Phase 1 Aspera Biomedicines, Inc. · Duarte, California and 2 other locations · NCT07250646

• Momelotinib given before and after allogeneic bone marrow transplant for myelofibrosis

  This test will see if giving momelotinib around the time of allogeneic hematopoietic cell transplant is safe and tolerable for adults with intermediate- or high-risk myelofibrosis.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07104799

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• National registry for people with myelofibrosis and anemia in Germany.

  This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT06976918

• National registry for people with myelofibrosis and anemia in Germany.

  This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT06976918

• Post-transplant cyclophosphamide strategies to prevent graft-versus-host disease after mismatched unrelated donor stem cell transplant

  This platform tests whether adding different drug combinations with post-transplant cyclophosphamide prevents graft‑versus‑host disease better than the standard regimen for adults getting mismatched unrelated donor peripheral blood stem cell transplants for blood cancers.

  Recruiting at 13 sites Phase 2 Center for International Blood and Marrow Transplant Research · Birmingham, Alabama and 12 other locations · NCT06859424

• Extracorporeal iron purification with MEX-CD1 for patients with MDS or myelofibrosis

  This study will try using an external blood-filter device (MEX-CD1) to remove excess iron in transfusion-dependent patients with myelodysplastic syndrome or myelofibrosis who cannot tolerate standard chelation.

  Recruiting at 2 sites Hospices Civils de Lyon · Oullins-Pierre-Bénite and 1 other locations · NCT06781099

• Combining ruxolitinib and ulixertinib for treating myelofibrosis

  This study is testing if combining two medications, ruxolitinib and ulixertinib, can help people with myelofibrosis who haven't had enough relief from ruxolitinib alone.

  Recruiting at 8 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 8 other locations · NCT06773195

• Haploidentical stem cell transplantation for myelofibrosis

  This study is testing a new type of stem cell transplant for people with myelofibrosis to see if it can help those who don’t have a matched donor and improve their chances of recovery.

  Recruiting Peking University People's Hospital · Beijing · NCT06674382

• Tasquinimod treatment for patients with myelofibrosis who can't tolerate JAK inhibitors

  This study is testing if tasquinimod can be a safe and effective treatment for people with myelofibrosis who can't tolerate JAK inhibitors.

  Recruiting Phase 1/2 Stichting Hemato-Oncologie voor Volwassenen Nederland · Aachen and 5 other locations · NCT06605586

• Observational study on patients with myelofibrosis in Europe

  This study is collecting information from patients with myelofibrosis across Europe to better understand the disease and improve how it's diagnosed and treated.

  Recruiting at 24 sites FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · Yerevan and 26 other locations · NCT06533813

• Combining Momelotinib and Luspatercept for Myelofibrosis Treatment

  This study is testing if combining two medications, momelotinib and luspatercept, can help people with myelofibrosis who need blood transfusions feel better and reduce their transfusion needs.

  Recruiting at 33 sites Phase 2 GlaxoSmithKline · Ann Arbor, Michigan and 32 other locations · NCT06517875

• Observational study on ruxolitinib for myelofibrosis patients

  This study looks at how well ruxolitinib works for people with myelofibrosis and how different factors affect their long-term survival.

  Recruiting at 26 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Cosenza, Calabria and 25 other locations · NCT06516406

• Adding navtemadlin to ruxolitinib for myelofibrosis patients with poor response

  This study is testing if adding a new drug called navtemadlin to ruxolitinib can help myelofibrosis patients who aren't doing well on ruxolitinib alone.

  Recruiting at 214 sites Phase 3 Kartos Therapeutics, Inc. · Birmingham, Alabama and 214 other locations · NCT06479135

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

• Evaluating GLB-001 for patients with myeloid malignancies

  This study is testing a new oral treatment called GLB-001 to see if it is safe and effective for people with certain types of blood cancers that have come back or didn't respond to other treatments.

  Recruiting at 14 sites Phase 1 Hangzhou GluBio Pharmaceutical Co., Ltd. · Hefei, Anhui and 13 other locations · NCT06378437

• Evaluating the safety and effectiveness of bomedemstat for blood disorders

  This study is trying to see how safe and effective bomedemstat is for people with blood disorders like essential thrombocythemia and myelofibrosis who have been doing well on the treatment for at least six months.

  Recruiting at 18 sites Phase 3 Merck Sharp & Dohme LLC · Ann Arbor, Michigan and 20 other locations · NCT06351631

• Using high doses of ruxolitinib and stem cell transplant for myelofibrosis patients with enlarged spleens

  This study is testing if giving high doses of ruxolitinib and busulfan before a stem cell transplant can help people with myelofibrosis and enlarged spleens live longer and have better recovery after the transplant.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06345495

• Using advanced imaging to evaluate myelofibrosis

  This study is testing new imaging techniques to see if they can help doctors better understand and monitor myelofibrosis without needing invasive procedures like bone marrow biopsies.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06164561

• Treatment of Myelofibrosis with TQ05105 and TQB3617

  This study is testing a new combination of TQ05105 tablets and TQB3617 capsules to see if it can help people with intermediate- and high-risk Myelofibrosis feel better.

  Recruiting at 2 sites Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Guangzhou, Guangdong and 21 other locations · NCT06122831

• Curcumin for treating inflammation and symptoms in blood disorders

  This study is testing if a curcumin supplement can help reduce inflammation and improve symptoms in people with certain blood disorders.

  Recruiting at 2 sites Phase 2 University of Southern California · Los Angeles, California and 1 other locations · NCT06063486

• Vaccination to prevent CMV infection in stem cell transplant patients

  This study is testing a new vaccine to see if it can help prevent CMV infections in patients receiving stem cell transplants from related donors.

  Recruiting at 3 sites Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06059391

• Evaluating Selinexor for Myelofibrosis with Low Platelet Counts

  This study is testing if a new drug called selinexor can help people with myelofibrosis and low platelet counts feel better and reduce their spleen size.

  Recruiting at 70 sites Phase 2 Karyopharm Therapeutics Inc · Duarte, California and 69 other locations · NCT05980806

• Telehealth program for advance care planning in older adults with myeloid malignancies

  This study tests if a telehealth program that helps older adults with blood cancers talk about their serious illness and make healthcare plans can reduce their anxiety and improve communication with doctors.

  Recruiting University of Rochester · Rochester, New York · NCT05875805

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

• Understanding the genetic structure of ASXL1-mutated myelofibrosis

  This study is trying to understand how ASXL1 mutations affect the survival and risk of leukemia in people with myelofibrosis by looking at blood samples from 50 patients over four years.

  Recruiting at 7 sites University Hospital, Angers · Angers and 12 other locations · NCT05710211

• Transplantation with Pegylated Interferon for Myelofibrosis

  This study is testing a new treatment using pegylated interferon for people with myelofibrosis who have received a stem cell transplant to see how safe it is and what the right dose should be.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT05535764

• New treatment for myelofibrosis using CK0804 with ruxolitinib

  This study is testing a new treatment called CK0804 for people with myelofibrosis who haven't felt better on ruxolitinib to see if it can help them more.

  Recruiting at 3 sites Phase 1 Cellenkos, Inc. · Sacramento, California and 3 other locations · NCT05423691

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

• Combining TL-895 with Ruxolitinib for treating Myelofibrosis

  This study is testing if combining TL-895 with Ruxolitinib can help people with Myelofibrosis feel better, especially those who haven't responded well to Ruxolitinib alone.

  Recruiting at 19 sites Phase 1/2 Telios Pharma, Inc. · Birmingham, Alabama and 18 other locations · NCT05280509

• Finding the best dose of N-Acetylcysteine for patients with blood disorders

  This study is testing the best dose of N-Acetylcysteine to see if it can help people with certain blood disorders feel better while they continue their usual treatments.

  Recruiting Phase 1/2 University of California, Irvine · Irvine, California and 1 other locations · NCT05123365

• Evaluating KER-050 for treating Myelofibrosis

  This study is testing a new treatment called KER-050 to see if it can help people with Myelofibrosis improve their blood cell counts and overall quality of life, both on its own and with another medication.

  Recruiting at 39 sites Phase 2 Takeda · Concord, New South Wales and 45 other locations · NCT05037760

• Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients

  This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.

  Recruiting Phase 2 Thomas Jefferson University · Philadephia, Pennsylvania · NCT05031897

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Oral treatment with LP-118 for patients with various blood cancers

  This study is testing a new oral treatment called LP-118 to see if it is safe and can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting at 8 sites Phase 1 Newave Pharmaceutical Inc · Chicago, Illinois and 7 other locations · NCT04771572

• Oral Nuvisertib for Patients with Myelofibrosis

  This study is testing a new oral medication called nuvisertib to see if it can help people with myelofibrosis who haven't had success with other treatments.

  Recruiting at 87 sites Phase 1/2 Sumitomo Pharma America, Inc. · Birmingham, Alabama and 90 other locations · NCT04176198

• Using hyperbaric oxygen therapy with stem cell transplants

  This study is testing whether hyperbaric oxygen therapy can help patients with chronic leukemias and myelofibrosis who are getting stem cell transplants feel better and recover more effectively.

  Recruiting Early Phase 1 University of Rochester · Rochester, New York · NCT03964506

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

• Assessing Hematopoietic Cell Transplantation for Myelofibrosis

  This study is trying to see if patients with myelofibrosis who receive a stem cell transplant do better than those who didn't have the transplant.

  Recruiting Center for International Blood and Marrow Transplant Research · Minneapolis, Minnesota · NCT02934477

• Using MRI to assess myelofibrosis

  This study is testing if special MRI scans can help doctors see how severe myelofibrosis is and how well treatments are working for patients.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT01973881

NIH-funded research (17)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Strategies to deplete myelofibrosis stem cells using HDM2/p53 pathway

  A patient-focused program tests a therapy that may selectively reduce disease-causing blood stem cells in people with myelofibrosis.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11399028

• Megakaryocyte changes in myelofibrosis and its progression to leukemia

  A scientist-guided project will study how abnormal megakaryocytes and signals like TGF-β and IL-13 may drive progression from myelofibrosis toward acute leukemia, with potential implications for future treatments.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11399019

• Molecular clues and new therapies for myelofibrosis and related blood cancers

  This grant supports research to understand what drives myelofibrosis and related disorders and to develop new treatment ideas for patients.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11399012

• Myelofibrosis and the bone marrow environment: how inflammation changes blood production

  A doctor-researcher is studying how inflammation in the bone marrow affects the blood-forming system in people with myeloproliferative neoplasms (MPNs) to find ways to prevent scarring and leukemia.

  NIH research Washington University · Saint Louis, United States · NIH-11385368

• Early detection of treatment response in myelofibrosis using a new imaging technology

  A new, quick imaging method could tell patients with myelofibrosis early whether a treatment is working.

  NIH research University of Houston · Houston, United States · NIH-11384215

• MYC-driven vulnerability in myelofibrosis could guide new therapies

  A new project is exploring how the MYC protein contributes to myelofibrosis and whether it can be targeted to help people with this blood cancer.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11329078

• MRI markers to monitor bone marrow in myelofibrosis

  Advanced MRI scans will be used to see bone marrow changes in people with myelofibrosis so doctors can tell sooner whether new targeted drugs are working.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11231743

• Targeting the stem cells that drive myelofibrosis

  Using drugs that boost the tumor-suppressor p53 to help remove the abnormal bone marrow stem cells that cause myelofibrosis in people with the disease.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11094805

• How abnormal platelet‑making cells drive worsening primary myelofibrosis

  Looks at whether changes in megakaryocytes (the cells that make platelets) and the signals they release make primary myelofibrosis worse for people with the disease.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11094801

• Molecular causes and new treatments for myelofibrosis

  This project is developing new treatments that target gene changes, inflammation, and epigenetic pathways to help people with myelofibrosis and related blood cancers.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11094800

• Exploring a new treatment target for myelofibrosis

  This study is looking at a new way to help people with myelofibrosis, a tough blood cancer, by exploring how a protein called MYC affects the disease and finding new treatments for those who haven't had success with current options.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11089310

• How pyruvate affects the development of myofibroblasts in myelofibrosis.

  This study is looking at how changing the way certain cells in your bone marrow use energy might help stop the scarring that happens in myelofibrosis, with the hope of finding new treatments that could improve your blood cell production and ease your symptoms.

  NIH research University of Utah · Salt Lake City, United States · NIH-11065017

• Using MRI to improve monitoring of myelofibrosis treatment

  This study is exploring new MRI methods to help doctors see how well treatments are working for people with myelofibrosis, a type of blood cancer, without needing painful procedures like biopsies.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11018856

• Myelofibrosis affects blood cell production through specific signaling pathways

  This study is looking at how myelofibrosis affects the bone marrow, which is important for making blood cells, and it aims to find new ways to help improve blood cell production and prevent serious issues like acute leukemia by understanding the signals that disrupt this process.

  NIH research Washington University · Saint Louis, United States · NIH-10887174

• Investigating the role of IL-1 signaling in myelofibrosis

  This study is looking at how a protein called IL-1 affects myelofibrosis, a serious blood condition, in hopes of finding new ways to treat it and help patients feel better.

  NIH research University of Virginia · Charlottesville, United States · NIH-10804665

• Investigating the bone marrow environment in myelofibrosis

  This study is looking at how the environment in the bone marrow affects primary myelofibrosis, a serious blood condition, and aims to find new treatments that could help improve outcomes for patients like you.

  NIH research Columbia University Health Sciences · New York, United States · NIH-10755697

• Investigating the role of a specific gene in myelofibrosis

  This study is looking at how a gene called PTPN11 might help us find new treatments for myelofibrosis, a serious blood disorder, by seeing how blocking this gene affects blood cell growth in patients, especially those with a common mutation.

  NIH research University of Virginia · Charlottesville, United States · NIH-10545076

Related topics

Quick answers

How many Myelofibrosis clinical trials are recruiting right now?

51, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 42 countries. The most sites are in United States (36 trials), Germany (10 trials), Italy (10 trials), France (9 trials), Spain (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 13, Phase 1/2: 10, Phase 1: 9, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →